BRIEF-EMA's CHMP Recommends Extensions Of Indication Imfinzi

Jan 31 (Reuters) - EMA:

• EMA SAYS CHMP RECOMMENDS EXTENSIONS OF INDICATION FOR BREYANZI, IMFINZI, OPDIVO, RONAPREVE, RXULTI, SIVEXTRO, SLENYTO AND YERVOY

• EMA SAYS CHMP RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR CAPVAXIVE -WEBSITE

• EMA SAYS CHMP GRANTED POSITIVE OPINION FOR TIVDAK (TISOTUMAB VEDOTIN) FOR TREATMENT OF RECURRENT OR METASTATIC CERVICAL CANCER

• EMA SAYS CHMP ADOPTED POSITIVE OPINIONS FOR BIOSIMILAR MEDICINES PAVBLU (AFLIBERCEPT) AND ITS DUPLICATE SKOJOY (AFLIBERCEPT)

• EMA SAYS CHMP APPLICATIONS FOR INITIAL MARKETING AUTHORISATION WITHDRAWN FOR DATOPOTAMAB DERUXTECAN DAIICHI SANKYO

• EMA SAYS CHMP ADOPTED POSITIVE OPINION FOR DATROWAY (DATOPOTAMAB DERUXTECAN) FOR, THE TREATMENT OF BREAST CANCER

• EMA SAYS CHMP POSITIVE SCIENTIFIC OPINION FOR IVERMECTIN/ALBENDAZOLE FOR TREATMENT OF INFECTIONS CAUSED BY SEVERAL TYPES OF WORM PARASITES

• EMA SAYS CHMP CONSIDER EUROPEAN COMMISSION'S REQUEST TO CONSIDER INFORMATION ON SAFETY OF LEQEMBI,PROVIDE RESPONSE AFTER PLENARY MEETING IN FEB

Source text: [ID:]

Further company coverage: AZN.L